Alchemia CEO leaves as Calzada gets a new one
13 November, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board.
Govt consults on boosting the commercial returns from research
11 November, 2014A key element of the Industry Innovation and Competitiveness Agenda has begun consultation, with the Australian Government releasing the discussion paper 'Boosting the Commercial Returns from Research'.
Innate commences dosing in SPMS trial
11 November, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) is dosing patients in a phase IIb trial of its MIS416 candidate in secondary progressive multiple sclerosis, and plans to activate a third site tomorrow.
Bionomics gets approval for BNC210 trial
11 November, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has secured approval for a phase Ib trial of anxiety and depression drug candidate BNC210, and will soon apply to conduct a phase II trial in anxiety.
Global Kinetics adds former EMA head to board
10 November, 2014 by Dylan Bushell-EmblingFormer EMA chief Dr Thomas Lönngren has joined the board of Global Kinetics, to help the company commercialise its Parkinson's symptom monitoring device.
Meeting of leading minds at key summit to support Australia's advanced manufacturing
06 November, 2014A critical mass of Australian leaders will set their collective mind to support Australia's future manufacturing industry at a summit next week in Sydney.
Medical devices on trial
05 November, 2014 by Susan WilliamsonMedical technology company Rhinomed is using its BreatheAssist technology platform to develop nasal devices for sport, snoring, sleep apnoea and drug delivery.
CNS, BDC to join forces for biotech consulting
05 November, 2014 by Dylan Bushell-EmblingClinical Network Services has entered a partnership to expand its consultancy expertise, and has appointed a principal consultant for its new London office.
IDT to acquire 23 more generic drugs
04 November, 2014 by Dylan Bushell-EmblingIDT Australia (ASX:IDT) has entered a conditional deal to acquire 23 previously marketed generic drugs for conditions including Parkinson's, depression and pain.
Government package to drive innovation
03 November, 2014The final part of the government's Entrepreneurs Infrastructure Program, the Accelerating Commercialisation stream, has been launched.
AusBiotech announces new chairman and directors
31 October, 2014AusBiotech has announced that a new chairman and three new directors were appointed to its board at the Annual General Meeting on the Gold Coast. CEO of BioDiem and existing AusBiotech director Julie Phillips was appointed Chairman, taking the mantle from long-serving chairman Dr Deborah Rathjen, and the board welcomed Serina Cucuzza, Barry Thomas and Serg Duchini as directors.
Pharmaxis starts recruiting for Bronchitol trial
31 October, 2014 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has recruited the first patient for a phase III trial of Bronchitol in cystic fibrosis, designed as part of the company's FDA application.
Feedback invited on boosting commercial returns
30 October, 2014The government is seeking input from the research sector and industry on its strategy to boost commercial returns from research.
Johnson & Johnson Innovation Industry Excellence Awards recognise biotechnology leaders at AusBiotech 2014
30 October, 2014Medtech featured strongly when the prestigious Johnson & Johnson Innovation Industry Excellence Awards 2014 were announced, recognising those at the forefront of Australia's world-class biotech, medical technology and healthcare sectors in Australia.
GM crops: new directions
29 October, 2014 by Graeme O'NeillAustralia's GM crop revolution has stalled, after an auspicious debut in 1989 when South Australia became the first state in the world to release a genetically modified organism into the environment.
